Tab Nicardipine

# Tab nicardipine ## Overview - **Classification**: Dihydropyridine Calcium Channel Blocker (CCB) - **Mechanism**: Inhibits calcium ion influx into vascular smooth muscle, causing peripheral vasodilation and reduced peripheral vascular resistance. ## Primary Indications 1. **Chronic Essential Hypertension** - Long-term management of high blood pressure. ## Adult Dosing ### Standard Dosing **Chronic Essential Hypertension (Immediate-Release)** - **Dose**: Initiate with **20 mg** - **Frequency**: Three times daily (TID) - **Route**: Oral - **Maximum Dose**: **40 mg** TID (**120 mg/day**) - **Special Considerations**: Doses can be titrated every 3 days. **Chronic Essential Hypertension (Sustained-Release - SR)** - **Dose**: Initiate with **30 mg** - **Frequency**: Twice daily (BID) - **Route**: Oral - **Maximum Dose**: **60 mg** BID (**120 mg/day**) - **Special Considerations**: May be preferred for improved adherence. ### Dose Adjustments - **Renal Impairment**: Initiate at lower doses, e.g., **10 mg TID** (IR) or **20 mg BID** (SR). Titrate slowly with close monitoring. - **Hepatic Impairment**: Initiate at lower doses, e.g., **10 mg TID** (IR) or **20 mg BID** (SR). Titrate slowly due to increased half-life. - **Elderly Patients**: Start with lower doses (e.g., **10 mg TID** IR or **20 mg BID** SR). Titrate slowly due to potential increased sensitivity and reduced clearance. ## Pediatric Dosing *Oral nicardipine is generally **not recommended** for pediatric chronic hypertension due to limited data, lack of age-appropriate formulations, and availability of preferred agents.* ### Neonates (0-28 days) - **Not Recommended**: Limited data for safety and efficacy of oral formulation. ### Infants (1-12 months) - **Not Recommended**: Limited data for safety and efficacy of oral formulation. ### Children (1-12 years) - **Not Recommended**: Limited data for safety and efficacy of oral formulation. ### Adolescents (13-18 years) - **Special Consideration**: If used off-label for chronic hypertension, **start low (e.g., 20 mg TID IR or 30 mg BID SR)**. - **Frequency**: Based on formulation (TID for IR, BID for SR). - **Maximum**: **Adult maximum dose** (**120 mg/day**). - **Special Notes**: Use only when other options are unsuitable; close monitoring is crucial. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to nicardipine or other dihydropyridine CCBs. - **Absolute**: Advanced aortic stenosis (risk of exacerbating outflow obstruction). - **Relative**: Acute myocardial infarction or unstable angina (unless specifically used to treat vasospasm). ### Common Adverse Effects - **Very Common (>10%)**: Headache, dizziness, flushing, peripheral edema. - **Common (1-10%)**: Nausea, palpitations, tachycardia, asthenia. - **Serious but Rare**: Symptomatic hypotension, syncope, exacerbation of angina, hepatotoxicity. ### Key Drug Interactions - **Beta-blockers**: Increased risk of bradycardia and heart block. Monitor heart rate and blood pressure. - **Cimetidine**: Increases nicardipine plasma concentrations. Consider nicardipine dose reduction. - **Cyclosporine/Tacrolimus**: Nicardipine can increase levels of these immunosuppressants. Monitor immunosuppressant levels closely. - **Grapefruit juice**: Can increase nicardipine levels due to CYP3A4 inhibition. **Avoid concurrent use**. ## Monitoring & Follow-up - **Before Treatment**: Baseline blood pressure, heart rate, renal and hepatic function tests. - **During Treatment**: Blood pressure (regularly), heart rate, signs of peripheral edema, symptoms of dizziness/lightheadedness. - **Clinical Signs**: Watch for excessive hypotension, worsening angina, or signs of heart failure. ## Clinical Pearls - 💡 **Titration**: Adjust dose based on patient response and tolerability, usually every 3 days. - 💡 **Consistency**: Take at regular intervals for consistent blood pressure control. - 💡 **Edema**: Peripheral edema is common, usually benign; may be managed by combining with an ACE inhibitor or ARB. - 💡 **Discontinuation**: Avoid abrupt withdrawal to prevent rebound hypertension. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.